Galmed Pharmaceuticals (NASDAQ:GLMD) Coverage Initiated at StockNews.com

StockNews.com initiated coverage on shares of Galmed Pharmaceuticals (NASDAQ:GLMD) in a research report released on Thursday. The firm issued a sell rating on the biopharmaceutical company’s stock.

Separately, Maxim Group reiterated a “hold” rating on shares of Galmed Pharmaceuticals in a research note on Friday, April 4th.

Galmed Pharmaceuticals Stock Performance

Shares of Galmed Pharmaceuticals stock opened at $1.26 on Thursday. Galmed Pharmaceuticals has a one year low of $1.15 and a one year high of $23.80. The company has a market cap of $2.08 million, a P/E ratio of -0.08 and a beta of 0.49. The firm has a fifty day moving average of $1.54 and a two-hundred day moving average of $2.38.

Hedge Funds Weigh In On Galmed Pharmaceuticals

A hedge fund recently bought a new stake in Galmed Pharmaceuticals stock. Schonfeld Strategic Advisors LLC acquired a new position in shares of Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD) during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor acquired 25,400 shares of the biopharmaceutical company’s stock, valued at approximately $81,000. Schonfeld Strategic Advisors LLC owned 3.97% of Galmed Pharmaceuticals at the end of the most recent reporting period. 76.14% of the stock is currently owned by institutional investors.

About Galmed Pharmaceuticals

Galmed Pharmaceuticals Ltd., a biopharmaceutical company, focuses on the development of therapeutics for the treatment of liver diseases. It develops Aramchol, an oral therapy, which is in Phase III study for the treatment of non-alcoholic steato-hepatitis (NASH) in patients with overweight or obesity and who are pre-diabetic or type-II-diabetes mellitus.